Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease - Zerdes - 2020 -
SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12. - Abstract - Europe PMC
Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Cancers | Free Full-Text | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Natalie Dvali - Incoming tours manager - International Tour Operator Intercontinental LLC | LinkedIn
Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease - Zerdes - 2020 -
Ioannis Zerdes (ioanniszerdes) - Profile | Pinterest
Immune gene expression and response to chemotherapy in advanced breast cancer | British Journal of Cancer
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis - Cancer Treatment Reviews
Pertuzumab, Trastuzumab, and Docetaxel for Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia - Researcher | An App For Academics
Ioannis Zerdes - Postdoctoral Researcher - Karolinska Institutet | LinkedIn
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis Zerdes - Postdoctoral Researcher - Karolinska Institutet | LinkedIn
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
![PDF] Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b35807a7b2a40d1d66ecfaf04ea6916752e28c9b/38-Table5-1.png "PDF] Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy | Semantic Scholar")
PDF] Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy | Semantic Scholar
Ioannis Zerdes - Greece | Professional Profile | LinkedIn
Ioannis Zerdes (ioanniszerdes) - Profile | Pinterest
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
